APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nonstructural Protein 4B

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nonstructural Protein 4B Market Analysis and Forecast 2026-2032

19 December 2025194 pages

Choose your research edition.

Industry ResearchNonstructural Protein 4B Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Nonstructural Protein 4B Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Nonstructural Protein 4B Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nonstructural Protein 4B Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Nonstructural Protein 4B Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Nonstructural Protein 4B market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nonstructural Protein 4B is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nonstructural Protein 4B is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nonstructural Protein 4B is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nonstructural Protein 4B is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nonstructural Protein 4B include Johnson & Johnson, Merck & Co., Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals, Inc. and Gilead Sciences, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nonstructural Protein 4B, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nonstructural Protein 4B, also provides the revenue of main regions and countries. Of the upcoming market potential for Nonstructural Protein 4B, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nonstructural Protein 4B revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nonstructural Protein 4B market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nonstructural Protein 4B revenue, projected growth trends, production technology, application and end-user industry.

Nonstructural Protein 4B Segment by Company

Johnson & Johnson

Merck & Co., Inc.

GlaxoSmithKline Plc

Inovio Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Nonstructural Protein 4B Segment by Type

GSK-8853

INO-8000

PTC-725

RL-15A

Others

Nonstructural Protein 4B Segment by Application

Hospital

Clinic

Others

Nonstructural Protein 4B Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonstructural Protein 4B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nonstructural Protein 4B and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonstructural Protein 4B.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nonstructural Protein 4B in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nonstructural Protein 4B company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nonstructural Protein 4B revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nonstructural Protein 4B Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. GSK-8853 Major Player Table 3. INO-8000 Major Player Table 4. PTC-725 Major Player Table 5. RL-15A Major Player Table 6. Others Major Player Table 7. Global Nonstructural Protein 4B Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Player Table 9. Clinic Major Player Table 10. Others Major Player Table 11. Nonstructural Protein 4B Industry Trends Table 12. Nonstructural Protein 4B Industry Drivers Table 13. Nonstructural Protein 4B Industry Opportunities and Challenges Table 14. Nonstructural Protein 4B Industry Restraints Table 15. Global Nonstructural Protein 4B Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nonstructural Protein 4B Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nonstructural Protein 4B Market Share by Region (2021-2026) Table 18. Global Nonstructural Protein 4B Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nonstructural Protein 4B Market Share by Region (2027-2032) Table 20. Global Nonstructural Protein 4B Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nonstructural Protein 4B Revenue Market Share by Players (2021-2026) Table 22. Global Nonstructural Protein 4B Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nonstructural Protein 4B Key Players Headquarters & Area Served Table 24. Global Nonstructural Protein 4B Players, Product Type & Application Table 25. Global Nonstructural Protein 4B Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nonstructural Protein 4B by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nonstructural Protein 4B Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nonstructural Protein 4B Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nonstructural Protein 4B Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nonstructural Protein 4B Revenue Market Share by Type (2021-2026) Table 32. Global Nonstructural Protein 4B Revenue Market Share by Type (2027-2032) Table 33. Global Nonstructural Protein 4B Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nonstructural Protein 4B Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nonstructural Protein 4B Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nonstructural Protein 4B Revenue Market Share by Application (2021-2026) Table 37. Global Nonstructural Protein 4B Revenue Market Share by Application (2027-2032) Table 38. Johnson & Johnson Company Information Table 39. Johnson & Johnson Business Overview Table 40. Johnson & Johnson Nonstructural Protein 4B Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Johnson & Johnson Nonstructural Protein 4B Product Portfolio Table 42. Johnson & Johnson Recent Development Table 43. Merck & Co., Inc. Company Information Table 44. Merck & Co., Inc. Business Overview Table 45. Merck & Co., Inc. Nonstructural Protein 4B Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Merck & Co., Inc. Nonstructural Protein 4B Product Portfolio Table 47. Merck & Co., Inc. Recent Development Table 48. GlaxoSmithKline Plc Company Information Table 49. GlaxoSmithKline Plc Business Overview Table 50. GlaxoSmithKline Plc Nonstructural Protein 4B Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. GlaxoSmithKline Plc Nonstructural Protein 4B Product Portfolio Table 52. GlaxoSmithKline Plc Recent Development Table 53. Inovio Pharmaceuticals, Inc. Company Information Table 54. Inovio Pharmaceuticals, Inc. Business Overview Table 55. Inovio Pharmaceuticals, Inc. Nonstructural Protein 4B Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Inovio Pharmaceuticals, Inc. Nonstructural Protein 4B Product Portfolio Table 57. Inovio Pharmaceuticals, Inc. Recent Development Table 58. Gilead Sciences, Inc. Company Information Table 59. Gilead Sciences, Inc. Business Overview Table 60. Gilead Sciences, Inc. Nonstructural Protein 4B Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Gilead Sciences, Inc. Nonstructural Protein 4B Product Portfolio Table 62. Gilead Sciences, Inc. Recent Development Table 63. North America Nonstructural Protein 4B Revenue by Type (2021-2026) & (US$ Million) Table 64. North America Nonstructural Protein 4B Revenue by Type (2027-2032) & (US$ Million) Table 65. North America Nonstructural Protein 4B Revenue by Application (2021-2026) & (US$ Million) Table 66. North America Nonstructural Protein 4B Revenue by Application (2027-2032) & (US$ Million) Table 67. North America Nonstructural Protein 4B Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 68. North America Nonstructural Protein 4B Revenue by Country (2021-2026) & (US$ Million) Table 69. North America Nonstructural Protein 4B Revenue by Country (US$ Million) & (2027-2032) Table 70. Europe Nonstructural Protein 4B Revenue by Type (2021-2026) & (US$ Million) Table 71. Europe Nonstructural Protein 4B Revenue by Type (2027-2032) & (US$ Million) Table 72. Europe Nonstructural Protein 4B Revenue by Application (2021-2026) & (US$ Million) Table 73. Europe Nonstructural Protein 4B Revenue by Application (2027-2032) & (US$ Million) Table 74. Europe Nonstructural Protein 4B Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. Europe Nonstructural Protein 4B Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Nonstructural Protein 4B Revenue by Country (US$ Million) & (2027-2032) Table 77. China Nonstructural Protein 4B Revenue by Type (2021-2026) & (US$ Million) Table 78. China Nonstructural Protein 4B Revenue by Type (2027-2032) & (US$ Million) Table 79. China Nonstructural Protein 4B Revenue by Application (2021-2026) & (US$ Million) Table 80. China Nonstructural Protein 4B Revenue by Application (2027-2032) & (US$ Million) Table 81. Asia Nonstructural Protein 4B Revenue by Type (2021-2026) & (US$ Million) Table 82. Asia Nonstructural Protein 4B Revenue by Type (2027-2032) & (US$ Million) Table 83. Asia Nonstructural Protein 4B Revenue by Application (2021-2026) & (US$ Million) Table 84. Asia Nonstructural Protein 4B Revenue by Application (2027-2032) & (US$ Million) Table 85. Asia Nonstructural Protein 4B Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Asia Nonstructural Protein 4B Revenue by Region (US$ Million) & (2021-2026) Table 87. Asia Nonstructural Protein 4B Revenue by Region (US$ Million) & (2027-2032) Table 88. SAMEA Nonstructural Protein 4B Revenue by Type (2021-2026) & (US$ Million) Table 89. SAMEA Nonstructural Protein 4B Revenue by Type (2027-2032) & (US$ Million) Table 90. SAMEA Nonstructural Protein 4B Revenue by Application (2021-2026) & (US$ Million) Table 91. SAMEA Nonstructural Protein 4B Revenue by Application (2027-2032) & (US$ Million) Table 92. SAMEA Nonstructural Protein 4B Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. SAMEA Nonstructural Protein 4B Revenue by Country (2021-2026) & (US$ Million) Table 94. SAMEA Nonstructural Protein 4B Revenue by Country (US$ Million) & (2027-2032) Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Nonstructural Protein 4B Image Figure 2. Global Nonstructural Protein 4B Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nonstructural Protein 4B Market Size Share 2021 VS 2025 VS 2032 Figure 4. GSK-8853 Image Figure 5. INO-8000 Image Figure 6. PTC-725 Image Figure 7. RL-15A Image Figure 8. Others Image Figure 9. Global Nonstructural Protein 4B Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Nonstructural Protein 4B Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Clinic Image Figure 13. Others Image Figure 14. Global Nonstructural Protein 4B Market Size (US$ Million) & (2021-2032) Figure 15. Global Nonstructural Protein 4B Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nonstructural Protein 4B Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nonstructural Protein 4B Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nonstructural Protein 4B Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nonstructural Protein 4B Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nonstructural Protein 4B Revenue Market Share by Type (2021-2032) Figure 22. Global Nonstructural Protein 4B Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nonstructural Protein 4B Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nonstructural Protein 4B Revenue Market Share by Application (2021-2032) Figure 25. North America Nonstructural Protein 4B Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nonstructural Protein 4B Revenue Share by Type (2021-2032) Figure 27. North America Nonstructural Protein 4B Revenue Share by Application (2021-2032) Figure 28. North America Nonstructural Protein 4B Revenue Share by Country (2021-2032) Figure 29. United States Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nonstructural Protein 4B Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nonstructural Protein 4B Revenue Share by Type (2021-2032) Figure 34. Europe Nonstructural Protein 4B Revenue Share by Application (2021-2032) Figure 35. Europe Nonstructural Protein 4B Revenue Share by Country (2021-2032) Figure 36. Germany Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nonstructural Protein 4B Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nonstructural Protein 4B Revenue Share by Type (2021-2032) Figure 46. China Nonstructural Protein 4B Revenue Share by Application (2021-2032) Figure 47. Asia Nonstructural Protein 4B Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nonstructural Protein 4B Revenue Share by Type (2021-2032) Figure 49. Asia Nonstructural Protein 4B Revenue Share by Application (2021-2032) Figure 50. Asia Nonstructural Protein 4B Revenue Share by Region (2021-2032) Figure 51. Japan Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nonstructural Protein 4B Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nonstructural Protein 4B Revenue Share by Type (2021-2032) Figure 59. SAMEA Nonstructural Protein 4B Revenue Share by Application (2021-2032) Figure 60. SAMEA Nonstructural Protein 4B Revenue Share by Country (2021-2032) Figure 61. Brazil Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nonstructural Protein 4B Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • GSK-8853
  • INO-8000
  • PTC-725
  • RL-15A
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Johnson & Johnson
  • Merck & Co., Inc.
  • GlaxoSmithKline Plc
  • Inovio Pharmaceuticals, Inc.
  • Gilead Sciences, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nonstructural Protein 4B Market by Type
  3. 1.2.1 Global Nonstructural Protein 4B Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 GSK-8853
  5. 1.2.3 INO-8000
  6. 1.2.4 PTC-725
  7. 1.2.5 RL-15A
  8. 1.2.6 Others
  9. 1.3 Nonstructural Protein 4B Market by Application
  10. 1.3.1 Global Nonstructural Protein 4B Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Clinic
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nonstructural Protein 4B Market Dynamics
  1. 2.1 Nonstructural Protein 4B Industry Trends
  2. 2.2 Nonstructural Protein 4B Industry Drivers
  3. 2.3 Nonstructural Protein 4B Industry Opportunities and Challenges
  4. 2.4 Nonstructural Protein 4B Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nonstructural Protein 4B Market Perspective (2021-2032)
  2. 3.2 Global Nonstructural Protein 4B Growth Trends by Region
  3. 3.2.1 Global Nonstructural Protein 4B Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nonstructural Protein 4B Market Size by Region (2021-2026)
  5. 3.2.3 Global Nonstructural Protein 4B Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nonstructural Protein 4B Revenue by Players
  2. 4.1.1 Global Nonstructural Protein 4B Revenue by Players (2021-2026)
  3. 4.1.2 Global Nonstructural Protein 4B Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nonstructural Protein 4B Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nonstructural Protein 4B Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nonstructural Protein 4B Key Players Headquarters & Area Served
  7. 4.4 Global Nonstructural Protein 4B Players, Product Type & Application
  8. 4.5 Global Nonstructural Protein 4B Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nonstructural Protein 4B Market CR5 and HHI
  11. 4.6.3 2025 Nonstructural Protein 4B Tier 1, Tier 2, and Tier 3
5 Nonstructural Protein 4B Market Size by Type
  1. 5.1 Global Nonstructural Protein 4B Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nonstructural Protein 4B Revenue by Type (2021-2032)
  3. 5.3 Global Nonstructural Protein 4B Revenue Market Share by Type (2021-2032)
6 Nonstructural Protein 4B Market Size by Application
  1. 6.1 Global Nonstructural Protein 4B Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nonstructural Protein 4B Revenue by Application (2021-2032)
  3. 6.3 Global Nonstructural Protein 4B Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Nonstructural Protein 4B Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Nonstructural Protein 4B Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 Merck & Co., Inc.
  8. 7.2.1 Merck & Co., Inc. Company Information
  9. 7.2.2 Merck & Co., Inc. Business Overview
  10. 7.2.3 Merck & Co., Inc. Nonstructural Protein 4B Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co., Inc. Nonstructural Protein 4B Product Portfolio
  12. 7.2.5 Merck & Co., Inc. Recent Developments
  13. 7.3 GlaxoSmithKline Plc
  14. 7.3.1 GlaxoSmithKline Plc Company Information
  15. 7.3.2 GlaxoSmithKline Plc Business Overview
  16. 7.3.3 GlaxoSmithKline Plc Nonstructural Protein 4B Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Plc Nonstructural Protein 4B Product Portfolio
  18. 7.3.5 GlaxoSmithKline Plc Recent Developments
  19. 7.4 Inovio Pharmaceuticals, Inc.
  20. 7.4.1 Inovio Pharmaceuticals, Inc. Company Information
  21. 7.4.2 Inovio Pharmaceuticals, Inc. Business Overview
  22. 7.4.3 Inovio Pharmaceuticals, Inc. Nonstructural Protein 4B Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Inovio Pharmaceuticals, Inc. Nonstructural Protein 4B Product Portfolio
  24. 7.4.5 Inovio Pharmaceuticals, Inc. Recent Developments
  25. 7.5 Gilead Sciences, Inc.
  26. 7.5.1 Gilead Sciences, Inc. Company Information
  27. 7.5.2 Gilead Sciences, Inc. Business Overview
  28. 7.5.3 Gilead Sciences, Inc. Nonstructural Protein 4B Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Gilead Sciences, Inc. Nonstructural Protein 4B Product Portfolio
  30. 7.5.5 Gilead Sciences, Inc. Recent Developments
8 North America
  1. 8.1 North America Nonstructural Protein 4B Revenue (2021-2032)
  2. 8.2 North America Nonstructural Protein 4B Revenue by Type (2021-2032)
  3. 8.2.1 North America Nonstructural Protein 4B Revenue by Type (2021-2026)
  4. 8.2.2 North America Nonstructural Protein 4B Revenue by Type (2027-2032)
  5. 8.3 North America Nonstructural Protein 4B Revenue Share by Type (2021-2032)
  6. 8.4 North America Nonstructural Protein 4B Revenue by Application (2021-2032)
  7. 8.4.1 North America Nonstructural Protein 4B Revenue by Application (2021-2026)
  8. 8.4.2 North America Nonstructural Protein 4B Revenue by Application (2027-2032)
  9. 8.5 North America Nonstructural Protein 4B Revenue Share by Application (2021-2032)
  10. 8.6 North America Nonstructural Protein 4B Revenue by Country
  11. 8.6.1 North America Nonstructural Protein 4B Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nonstructural Protein 4B Revenue by Country (2021-2026)
  13. 8.6.3 North America Nonstructural Protein 4B Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Nonstructural Protein 4B Revenue (2021-2032)
  2. 9.2 Europe Nonstructural Protein 4B Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nonstructural Protein 4B Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nonstructural Protein 4B Revenue by Type (2027-2032)
  5. 9.3 Europe Nonstructural Protein 4B Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nonstructural Protein 4B Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nonstructural Protein 4B Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nonstructural Protein 4B Revenue by Application (2027-2032)
  9. 9.5 Europe Nonstructural Protein 4B Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nonstructural Protein 4B Revenue by Country
  11. 9.6.1 Europe Nonstructural Protein 4B Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nonstructural Protein 4B Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nonstructural Protein 4B Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Nonstructural Protein 4B Revenue (2021-2032)
  2. 10.2 China Nonstructural Protein 4B Revenue by Type (2021-2032)
  3. 10.2.1 China Nonstructural Protein 4B Revenue by Type (2021-2026)
  4. 10.2.2 China Nonstructural Protein 4B Revenue by Type (2027-2032)
  5. 10.3 China Nonstructural Protein 4B Revenue Share by Type (2021-2032)
  6. 10.4 China Nonstructural Protein 4B Revenue by Application (2021-2032)
  7. 10.4.1 China Nonstructural Protein 4B Revenue by Application (2021-2026)
  8. 10.4.2 China Nonstructural Protein 4B Revenue by Application (2027-2032)
  9. 10.5 China Nonstructural Protein 4B Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nonstructural Protein 4B Revenue (2021-2032)
  2. 11.2 Asia Nonstructural Protein 4B Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nonstructural Protein 4B Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nonstructural Protein 4B Revenue by Type (2027-2032)
  5. 11.3 Asia Nonstructural Protein 4B Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nonstructural Protein 4B Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nonstructural Protein 4B Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nonstructural Protein 4B Revenue by Application (2027-2032)
  9. 11.5 Asia Nonstructural Protein 4B Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nonstructural Protein 4B Revenue by Country
  11. 11.6.1 Asia Nonstructural Protein 4B Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nonstructural Protein 4B Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nonstructural Protein 4B Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nonstructural Protein 4B Revenue (2021-2032)
  2. 12.2 SAMEA Nonstructural Protein 4B Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nonstructural Protein 4B Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nonstructural Protein 4B Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nonstructural Protein 4B Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nonstructural Protein 4B Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nonstructural Protein 4B Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nonstructural Protein 4B Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nonstructural Protein 4B Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nonstructural Protein 4B Revenue by Country
  11. 12.6.1 SAMEA Nonstructural Protein 4B Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nonstructural Protein 4B Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nonstructural Protein 4B Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst